CD123.t-haNK

N/A

Report date: 2021/12/24 10:29:13

Base Information

Drug NameCD123.t-haNK
Drug Alias NameCD123.t-haNK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmunitybio Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio IncNantkwest Inc
Inactive CompaniesN/A
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A